JPS6366286B2 - - Google Patents
Info
- Publication number
- JPS6366286B2 JPS6366286B2 JP11885080A JP11885080A JPS6366286B2 JP S6366286 B2 JPS6366286 B2 JP S6366286B2 JP 11885080 A JP11885080 A JP 11885080A JP 11885080 A JP11885080 A JP 11885080A JP S6366286 B2 JPS6366286 B2 JP S6366286B2
- Authority
- JP
- Japan
- Prior art keywords
- thienylthio
- cancer
- acetic acid
- anticancer
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- FGTPHFGZGZOZGD-UHFFFAOYSA-N 2-thiophen-2-ylsulfanylacetic acid Chemical compound OC(=O)CSC1=CC=CS1 FGTPHFGZGZOZGD-UHFFFAOYSA-N 0.000 claims description 9
- 125000005907 alkyl ester group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 10
- 229940041181 antineoplastic drug Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000052812 Ornithine decarboxylases Human genes 0.000 description 4
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- -1 superoxide anions Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 150000002266 vitamin A derivatives Chemical class 0.000 description 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- ZAVLMIGIVYJYMU-UHFFFAOYSA-N 4-(5-nitrofuran-2-yl)-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2OC(=CC=2)[N+]([O-])=O)=C1 ZAVLMIGIVYJYMU-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- YNUNTAWVARFSQZ-UHFFFAOYSA-N ethyl 2-thiophen-2-ylsulfanylacetate Chemical compound CCOC(=O)CSC1=CC=CS1 YNUNTAWVARFSQZ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- MZIOYHCBNQNFHI-UHFFFAOYSA-N n-(4-hydroxybutyl)nitrous amide Chemical compound OCCCCNN=O MZIOYHCBNQNFHI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11885080A JPS5742622A (en) | 1980-08-27 | 1980-08-27 | Anticancer agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11885080A JPS5742622A (en) | 1980-08-27 | 1980-08-27 | Anticancer agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5742622A JPS5742622A (en) | 1982-03-10 |
| JPS6366286B2 true JPS6366286B2 (cs) | 1988-12-20 |
Family
ID=14746678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11885080A Granted JPS5742622A (en) | 1980-08-27 | 1980-08-27 | Anticancer agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5742622A (cs) |
-
1980
- 1980-08-27 JP JP11885080A patent/JPS5742622A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5742622A (en) | 1982-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0186505B1 (en) | Pharmaceutical compositions containing organogermanium compound and their use | |
| US6465505B1 (en) | Benzyl-substituted benzimidazoles | |
| US3655897A (en) | Anti-inflammatory agents | |
| TWI814693B (zh) | 高穩定性的驅除重金屬組合物及其用途、劑型和製備方法 | |
| HUP0100853A2 (hu) | Fekély kezelésére alkalmas nitrátsók és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
| KR940011244B1 (ko) | 신장 질환 치료제 | |
| WO2001056568A1 (en) | Remedies or preventives for digestive diseases containing diaminotrifluoromethylpyridine derivatives | |
| EP0087629A2 (en) | Antiinflammatory and/or analgesic 2,3-Diaryl-5-halo thiophenes | |
| JPS6366286B2 (cs) | ||
| PT97487A (pt) | Processo para a preparacao de sais de derivados de furano e de um complexo de bismuto com um acido carboxilico terapeuticamente uteis | |
| CN115703727B (zh) | 一种过硫化氢前药及其制药用途 | |
| CS198195B2 (en) | Process for preparing 4-imino-1,3-diazabicyclo/3,1,0/hexan-2-one | |
| WO2001000217A1 (en) | Medicinal compositions for preventing or treating diarrhea | |
| US4447437A (en) | Pharmaceutical composition and method for treatment of peptic ulcer | |
| US3852454A (en) | Treatment of rheumatoid arthritis | |
| CN114177177A (zh) | 一种乏氧肿瘤选择性激活前药的制备方法 | |
| JPS6183125A (ja) | 癌転移阻害剤 | |
| JPS5835186A (ja) | ジカルボキシアミノチアゾール誘導体およびそれを含有する免疫調節組成物 | |
| US3808197A (en) | Rutin-complexes and process for the preparation thereof | |
| JP2816227B2 (ja) | 抗潰瘍薬 | |
| JPH0120128B2 (cs) | ||
| JPS60190714A (ja) | 有機ゲルマニウム化合物を含有する薬剤組成物 | |
| JPS60208914A (ja) | 肝障害の予防、治療剤 | |
| JPH0260670B2 (cs) | ||
| JPH0534338B2 (cs) |